IntroductionAttention-deficit/hyperactivity disorder (ADHD) in adults often co-occurs with eating disorders (EDs), potentially through shared difficulties in emotional regulation, and executive functions. This study explored the associations between cognitive flexibility as a component of executive functions, core adult ADHD symptom dimensions and emotional eating-related eating behaviorsin adults with ADHD and healthy controls, within the framework of executive functions.MethodsThis case-control study included 76 adults with ADHD and 69 healthy controls. Participants completed the Self-Report Wender-Reimherr Adult Attention Deficit Disorder Scale (SR-WRAADDS), Emotional Eating Questionnaire (EEQ), Hospital Anxiety and Depression Scale, Cognitive Control and Flexibility Questionnaire (CCFQ), and Berg’s Card Sorting Test. Group differences were tested with t-tests, correlations with Spearman’s ρ, and hierarchical regression (Approval No: I11-798-23).ResultsThe ADHD group had significantly higher EEQ scores (t = 5.39, p =0.001). The ADHD group also showed lower CCFQ total score (t (125) = –5.52, p <0.001). EEQ scores were positively correlated with SR-WRAADDS Attention Deficit (ρ =0.331, p =0.003), and CCFQ Cognitive Control over Emotion (ρ = −0.256, p =0.02). Regression analysis identified attention deficit as the only significant predictor of the EEQ total scorein the ADHD group.DiscussionOur findings suggest that impairments in executive functioning—including cognitive flexibility, attentional regulation, and emotion-related control mechanisms—may play a more central role in the relationship between ADHD and emotional eating-related eating behaviors. Longitudinal studies are warrented to further elucidate these mechanisms.
Early Detection and AI-Based Management of Skin-Related Neglected Tropical Diseases in Sub-Saharan Africa by Frontline Health Workers
Conditions: Skin and Connective Tissue Diseases; Neglected Tropical Diseases; Leprosy; Buruli Ulcer; Cutaneous Leishmaniasis; Scabies; Mycetoma; Lymphatic Filariasis; Onchocerciasis; Tungiasis; Post Kala-Azar Dermal Leishmaniasis; Yaws; Podoconiosis
Interventions: Device: A mobile app with AI functionality for diagnosing skin-related NTDs
Sponsors: Kenya Medical Research Institute; Universidad Politecnica de Madrid; FACHHOCHSCHULE ZENTRALSCHWEIZ – HOCHSCHULE LUZERN; SHERWOOD HEALTHCARE SENEGAL SARL; King’s College London; TEACUP CONSULTING SL; MTU AUSTRALO ALPHA LAB; OMODI, AGASNA, ODIEMBO ADVOCATES LLP; OEUVRES HOSPITALIERES FRANCAISES DE L’ORDRE DE MALTE; ARMAUER HANSEN RESEARCH INSTITUTE; Leprosy and Tuberculosis Relief Initiative Nigeria; UNIVERSITE CATHOLIQUE DE BUKAVU
Not yet recruiting
Interventions: Device: A mobile app with AI functionality for diagnosing skin-related NTDs
Sponsors: Kenya Medical Research Institute; Universidad Politecnica de Madrid; FACHHOCHSCHULE ZENTRALSCHWEIZ – HOCHSCHULE LUZERN; SHERWOOD HEALTHCARE SENEGAL SARL; King’s College London; TEACUP CONSULTING SL; MTU AUSTRALO ALPHA LAB; OMODI, AGASNA, ODIEMBO ADVOCATES LLP; OEUVRES HOSPITALIERES FRANCAISES DE L’ORDRE DE MALTE; ARMAUER HANSEN RESEARCH INSTITUTE; Leprosy and Tuberculosis Relief Initiative Nigeria; UNIVERSITE CATHOLIQUE DE BUKAVU
Not yet recruiting
Evidence of monkeypox virus clade IIb lineage A.2.2 in the Republic of the Congo and co-circulation of clade Ia, Ib and clade IIb
Nature Medicine, Published online: 03 April 2026; doi:10.1038/s41591-026-04256-2
Whole-genome phylogenetic analyses have identified a case of monkeypox virus clade IIb lineage in the Republic of the Congo and co-circulation of three clade lineages, emphasizing the importance of improved surveillance given the risk of possible recombination events in the future.
The exposome of brain aging across 34 countries
Nature Medicine, Published online: 03 April 2026; doi:10.1038/s41591-026-04302-z
Exposome analyses across 34 countries showed that social exposures were associated with faster functional brain aging and physical exposures with faster structural brain aging.
Target product profiles for treatments to delay or prevent symptomatic Alzheimer’s disease
Nature Medicine, Published online: 03 April 2026; doi:10.1038/s41591-026-04305-w
To accelerate therapeutic development and equip stakeholders with clear benchmarks, the authors outline target product profiles for therapies designed to delay or prevent the onset of clinical symptoms of Alzheimer’s disease.
Telehealth Mindfulness-based Intervention for Adolescents With Autism Spectrum Disorder and Their Caregivers
Conditions: Autism Spectrum Disorder
Interventions: Behavioral: MINDful TIME; Behavioral: Mindfulness Mobile App
Sponsors: Nicole Matthews, Ph.D.; Southwest Autism Research & Resource Center; Arizona State University
Recruiting
Interventions: Behavioral: MINDful TIME; Behavioral: Mindfulness Mobile App
Sponsors: Nicole Matthews, Ph.D.; Southwest Autism Research & Resource Center; Arizona State University
Recruiting
Opinion: Subscription pricing could expand access to HIV prevention breakthrough while controlling costs
Figure 2 from the PURPOSE-1 trial changed the world.
Between gray and red bars representing the study’s background HIV incidence and the arms randomized to receive oral pre-exposure prophylaxis (PrEP) was white space filled only by a previously unimaginable number: zero. Zero infections over one year among the 2,134 cisgender adolescent girls and young women who received the novel long-acting injectable antiretroviral lenacapavir.
Relatix Health Applies for ARIA Funding to Build Digital Trust for Neurodiverse Communities
We’re proud to share that Relatix Health has applied for funding from the UK’s Advanced Research and Invention Agency (ARIA) under its Trust Everything, Everywhere programme. This initiative explores how trust can be built across the digital and physical worlds, and we believe that conversation must include people whose minds work differently.
Our proposal focuses on one of the most pressing and least understood challenges of the digital age: how people with neurodevelopmental and neurodiverse conditions, including autism, ADHD, schizophrenia, borderline traits, and psychopathy, experience, interact with, and build trust in AI systems. In a world increasingly mediated by algorithms, the ways these systems interpret, respond to, and store our most personal thoughts and data matter profoundly.
Throughout history, individuals living with stigmatized neurocognitive conditions have been marginalized or misrepresented by institutions, by society, and now, potentially, by AI. Some may over-trust technology that feels neutral or supportive; others may under-trust it because of past harm or bias. We want to ensure that digital systems meet people where they are, building trust rather than eroding it, while protecting privacy and supporting quality of life, health, and wellbeing.
Through this work, Relatix Health aims to lead the way in ethical and inclusive neuro-AI design: protecting privacy, reducing stigma, and helping define standards for responsible data handling in the era of AI. Our goal is to make sure that the next generation of AI-driven tools, from chatbots to diagnostics, truly serves everyone, regardless of how their brain is wired.
We know how often things have already gone wrong, from chatbots unintentionally encouraging depressive or paranoid thoughts, to credit and gambling platforms optimizing for addiction or impulsive behaviour. These systems were not built with sufficient safeguards for people with neurodevelopmental conditions, who may react differently to AI-optimized interactions. Many respond by disengaging digitally, and may feel that an AI-driven world is a minefield because it was not built for them.
Join us in shaping a radically different future where cognitive diversity and digital trust can coexist, and AI tools are built to truly support and empower. To learn more about our mission or to collaborate, contact our team.